We evaluated the effect of high dose involved field radiotherapy and concurrent chemotherapy for treating patients with limited disease, small cell lung cancer. Materials and Methods: We reviewed the medical records of 37 patients who had a limited stage of small cell lung cancer. All the patients were treated with induction chemotherapy followed by definitive radiotherapy and concurrent chemotherapy. The radiation dose was 60 Gy for 31 patients and 50∼58 Gy for 6 patients with once-daily 2 Gy fractions. Elective nodal irradiation was not performed. The chemotherapy regimen was either combinations of etoposide and cisplatin or irinotecan and cisplatin. Prophylactic cranial irradiation of 25 Gy at 2.5 Gy per fraction was administered to the patients who had a complete or near complete response. The median follow-up period was 17 months (range, 5∼57). Results: The 2-year overall survival and locoregional control rates were both 55%. A complete response was achieved in 17 patients (46%), a partial response was achieved in 19 patients (51%) and 1 patient (3%) had progressive disease. Seven patients experienced tumor recurrence in the radiation field and four of those recurrences were isolated local recurrences. There was only one isolated regional recurrence outside the radiation field. Grade 3 treatment-related esophageal toxicity occurred in 2 patients. Two patients died of treatment-related pulmonary complications. Conclusion: Involved field radiotherapy of 60 Gy can achieve favorable survival and a low rate of isolated nodal failure outside the radiation field. However, a considerable number of patients still experienced in-field failure. Further studies to establish the optimal radiation doses and fractionation are needed in the future. (J Lung Cancer 2010;9(2):85 90)
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in Korea. Small cell lung cancer (SCLC) makes up approximately 13% of all the cases of lung cancer (1) . Approximately 30% of patients have limited-stage disease (LD-SCLC) (2) . Concurrent chemoradiotherapy with an etoposide plus cisplatin regimen and early thoracic radiation therapy (TRT) has been the standard therapy for LD-SCLC since the early 1990s (2-6).
The substitution of irinotecan for etoposide has been evaluated in an effort to improve the results (7) (8) (9) (10) (11) . With regard to the specifics of TRT administration, modest doses of TRT (45∼50 Gy) have traditionally been used. However, the local control rate of a total dose of 45 Gy, as assessed by a prospective randomized trial, was not good enough (12) . High-dose once-daily TRT could result in comparable or improved outcomes and toxicities (13) (14) (15) (16) . High radiation doses are correlated with improved local control (17) . However, treatment-related pneumonitis is a common complication that can lead to respiratory insufficiency and sometimes death.
Reduction of the radiation fields by omitting routine elective nodal irradiation could allow dose escalation without a significant increase of the treatment related toxicities. We retrospectively reviewed our data to evaluate the efficacy and safety of high dose once-daily involved field TRT for treating patients with LD-SCLC.
MATERIALS AND METHODS

1) Patients
Between May 2003 to December 2009, 51 consecutive LD-SCLC patients were treated with high dose TRT and concurrent chemotherapy at Seoul National University Bundang Hospital, Republic of Korea. From this group, the following patients were excluded: 6 patients who were treated with a total radiation dose less than 45 Gy, 5 patients who were treated with 45 Gy in twice-daily 1.5 Gy fractions, 2 patients who underwent surgical resection and 1 patient who received sequential chemotherapy and radiotherapy. The remaining 37 patients were analyzed in this retrospective study.
All the patients had their tumor diagnosed with pathologic confirmation. All the patients were examined with physical examination and staging work-ups that included the complete blood cell count, blood chemistry, chest X-ray, chest computed tomography (CT), bone scan and brain magnetic resonance imaging (MRI). Whole body positron emission tomography (PET) was performed in 28 patients.
2) Treatments
All thirty-seven patients were treated with induction chemotherapy is followed by definitive three-dimensional, conformal, involved field radiotherapy and concurrent chemotherapy. Gy at 2.5 Gy per fraction.
3) Evaluations and statistical analysis
The objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors criteria (18, 19) . The toxicities were scored according to the National 
RESULTS
1) Demographic data
Twenty nine of the patients (78%) were men and the median age was 60 years (range, 34∼79 years). All the patients had had stage IV disease (pleural nodules or effusion).
2) Tumor response, survival and patterns of failure
The overall response rate was 97% for all the patients. A CR was achieved in 17 patients (46%), a PR was achieved in 19 patients (51%) and 1 patient (3%) had progressive disease.
The median follow-up time was 17 months (range, 5∼57). We have been treated LD-SCLC with once-daily, 60 Gy, involved field postchemotherapy volume TRT with concurrent chemotherapy. The survival rates were comparable to those of the other recent trials and only one patient (3%) experienced isolated out of field regional failure. However, despite that a relatively high dose of 60 Gy was used, the in-field local recurrence rate was higher than expected. Seven patients (19%) experienced in-field local recurrence and four (11%) of these patients experienced isolated local failure as their first site of failure. This isolated in-field local recurrence rate is higher than those of the recent Dutch phase II trial: that Dutch trial reported a 5% rate of in-field local recurrence and a 3% rate of isolated local recurrence (24) . Although our study's overall locoregional control rates are comparable to those of the Intergroup study (12) , it is difficult to compare exact local control rates due to our shorter follow-up period. Further, other retrospective studies (16, 22 ) that used ≥50 Gy or 54 Gy of once-daily TRT showed superior local control rates (3 year local control rates of 61∼ 78%) than our study did.
Relatively high local recurrence rates might be due to a We can speculate that this delayed radiotherapy might be one of the reasons for the relatively high in-field local recurrences.
Treatment-related pneumonitis is a common complication that can lead to respiratory insufficiency and sometimes death.
Other studies using concurrent chemoradiotherapy have reported severe (≥ grade 3) treatment-related pneumonitis ranging from 4% to 9% and fatal pneumonitis ranging from 0 to 3% (9, 10, 12, 27) . In our study, 6 patients experienced grade 2 treatment-related pneumonitis and 2 patients died of treatmentrelated pulmonary complications. One patient expired from respiratory failure due to combined treatment-related pneumonitis, atypical pneumonia and disease progression. The other patient had underlying severe emphysema and that patient experienced dyspnea at 3 months after radiotherapy. This dyspnea was temporarily improved with prednisolone, but he died of acute exacerbation of interstitial lung disease 4 weeks later.
In conclusion, once-daily 60 Gy TRT with concurrent chemotherapy and starting the TRT after two cycles of chemotherapy showed favorable survival outcomes and reasonable toxicities in patients with LD-SCLC. Postchemotherapy volume involved field radiotherapy was safe, yet a considerable number of patients still experienced in-field failure. Further prospective studies to establish the optimal radiation doses, fractionation and timing are needed in the future.
